Tesla Launches Full SelfDriving Supervised in China After Regulatory Hurdles Facing Intense Local Competition Stellantis Turnaround Strategy and Oura IPO Highlight Mixed Market Signals Supreme Court Declines Metas Appeal in Vermont Instagram Lawsuit Arsenals Cultural Reach Brand Strength Amid OnField Challenges Q4 Earnings Season Sun Pharma Eicher Motors Lead Gains Hindalco Torrent Pharma See Decline Offer for Sale OFS Explained A Guide to How It Works on Stock Exchanges BR Q1 2026 Earnings Solid Earnings Beat Driven by Operational Strength Loar Holdings Inc LOAR Q1 2026 Earnings Stellar EPS Beat Signals Strong Operational Execution SBC Q1 2026 Earnings EPS Exceeds Estimates as Stock Dips Despite Strong Profitability PTHS Q1 2026 Earnings Narrowed Loss Per Share Beats Estimates No Revenue Yet EBC Q1 2026 Earnings EPS Misses Estimates Shares Dip on Surprise MDU Q1 2026 Earnings EPS Misses Estimates by 72 Stock Gains 15 Phibro Animal Health PAHC Holds Near Support Amid Modest Pullback Fate Therapeutics Rallies 95 as FATE Stock Breaks Above Key Support Level Telephone and Data Systems TDS Posts Minor Gain Key Levels in Focus John B Sanfilippo Son JBSS Rallies 238 as Support Holds Eyes Resistance at 8135 Aldabra 4 Liquidity Opportunity Vehicle ALOV Holds Steady at 993 as Traders Eye Support and Resistance Morgan Stanley Raises Price Target on Teradyne TER Amid Semiconductor Testing Demand FRMEP Q1 2026 Earnings Depositary Shares Deliver EPS Beat Driven by Solid Core Performance LMP Capital and Income Fund SCD Narrows Slightly Holding Near Resistance Is Estrella ESLAW stock a good option for investors How MacroGenics MGNX innovation pipeline shows in financials MGNX MacroGenics Q4 Earnings Beat Shrinks Loss by 22 How Intercorp IFS balances growth with profitability 123 20260508 How Synergy CHC SNYR responds to market challenges Parabolic 20260506 The quiet positioning of Star Bulk SBLK nobody discusses Flirts with Breakout 20260503 SATLW Satellogic expands global satellite imaging footprint as key driver of longterm sustainable revenue growth UNCY Unicycive Therapeutics reports wide Q4 2025 EPS miss shares dip slightly amid soft investor sentiment